title: [Chemotherapy for multiple myeloma].
abstract: The combination of the melphalan and prednisolone (MP) can induce objective responses in about 50% of patients with multiple myeloma (MM) since its introduction in 1960. Since then many combination chemotherapy regimens have been used, but a large metaanalysis showed that the combination of oral MP is as effective as combination regimens including intravenous drugs. In recent years, many novel agents (including bortezomib, thalidomide, and liposomal doxorubicin) have been developed for the MM treatment. More recently, MP has been used in combination with these novel agents. The combination treatment of MP and thalidomide, overall survival was significantly better than seen in the MP treatment. In the near future, primary induction therapy will be changed.
authors: First Department of Internal Medicine, Sapporo Medical University School of Medicine.
authors: Tadao
authors: T
authors: Ishida
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D015201:Meta-Analysis as Topic; D009101:Multiple Myeloma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008558:Melphalan